Neurofibrillary degeneration of the Alzheimer-type: An alternate pathway to neuronal apoptosis?

Biochemical Pharmacology

Volumn 66, Issue 8, 2003, Pages 1619-1625

  Hamdane, Malika ^a   Delobel, Patrice ^a   Sambo, Anne Véronique ^a   Smet, Caroline ^b   Bégard, Séverine ^a   Violleau, Anne ^a   Landrieu, Isabelle ^b   Delacourte, André ^a   Lippens, Guy ^b   Flament, Stéphane ^c   Buée, Luc ^a  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

AD; Alzheimer's disease; Amyloid precursor protein; APP; Cdk; Cdk5; Cell cycle; Cyclin dependent kinase; Neurofibrillary tangles; Neurofibrillary tangles (NFT); Neuronal death; NFT; Paired helical filaments; PHF; Pin1; Tau phosphorylation

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; EPITOPE; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN; PROTEIN P25; TAU PROTEIN; UNCLASSIFIED DRUG; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE;

ALZHEIMER DISEASE; APOPTOSIS; BIOACCUMULATION; CELL AGGREGATION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; COMPLEX FORMATION; CONFERENCE PAPER; DEGENERATIVE DISEASE; ENZYME ACTIVATION; HUMAN; MICROTUBULE; NERVE CELL; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; ANIMAL; METABOLISM; MITOSIS; NERVE DEGENERATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; CELL CYCLE; HUMANS; MITOSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLES; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; TAU PROTEINS;

EID: 0642375800     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00533-1     Document Type: Conference Paper

References (52)

1. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 1997;18:S1-2.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297(5580):2002;353- 356.
3. Delacourte A., Sergeant N., Buée L. Tauopathy upstream of the amyloid cascade in Alzheimer's disease. Brain Aging. 2:2002;16-17.
4. Buée L., Bussière T., Buée-Scherrer V., Delacourte A., Hof P.R. Tau isoforms in neurodegenerative disorders. Brain Res. Rev. 33:2000;95-130.
5. Delacourte A., Sergeant N., Champain D., Wattez A., Maurage C.A., Lebert F., Pasquier F., David J.P. Nonoverlapping but synergetic APP and Tau pathologies in sporadic Alzheimer's disease. Neurology. 59:2002;398-407.
6. Fewster P.H., Griffin-Brooks S., MacGregor J., Ojalvo-Rose E., Ball A. A topographical pathway by which histopathological lesions disseminate through the brain of patients with Alzheimer's disease. Dementia. 2:1991;121-132.
7. Stamer K., Vogel R., Thies E., Mandelkow E., Mandelkow E.M. Tau blocks traffic of organelles neurofilaments and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156(6):2002;1051-1063.
8. Neve R.L., McPhie D.L., Chen Y. Alzheimer's disease: a dysfunction of the amyloid precursor protein. Brain Res. 886:2000;54-66.
9. Su J.H., Anderson A.J., Cummings B.J., Cotman C.W. Immunohistochemical evidence for DNA fragmentation in neurons in the Alzheimer's disease brain. NeuroReport. 5:1994;2529-2533.
10. Guo Q., Fu W., Xie J., Luo H., Sells S.F., Geddes J.W., Bondada V., Rangnekar V.M., Mattson M.P. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. Nat. Med. 4(8):1998;957-962.
11. Broe M., Shepherd C.E., Milward E.A., Halliday G.M. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 101(6):2001;616-624.
12. Stadelmann C., Bruck W., Bancher C., Jellinger K., Lassmann H. Alzheimer's disease: DNA fragmentation indicates increased neuronal vulnerability but not apoptosis. J. Neuropathol. Exp. Neurol. 57:1998;456-464.
13. Tsang S.Y., Tam S.C., Bremner I., Burkitt M.J. Copper-1, 10-phenanthroline induces internucleosomal DNA fragmentation in HepG2 cells resulting from direct oxidation by the hydroxyl radical. Biochem. J. 317:1996;13-16.
14. Freeman R.S., Estus S., Johnson E.M. Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin D1 during programmed cell death. Neuron. 12(2):1994;343-355.
15. Herrup K., Busser J.C. The induction of multiple cell cycle events precede target-related neuronal death. Development. 121:1995;2385-2395.
16. Padmanabhan J., Park D.S., Greene L.A., Shelanski M.L. Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. J. Neurosci. 19:1999;8747-8756.
17. Liu D.X., Greene L.A. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res. 305(2):2001;217-228.
18. Katchanov J., Harms C., Gertz K., Hauck L., Waeber C., Hirt L., Priller J., van Harsdorf R., Brück W., Hörnagl H., Dirnagl U., Bhide P.G., Endres M. Mild cerebral ischemia induces loss of cyclin-dependent kinase inhibitors and activation of cell cycle machinery before delayed neuronal cell death. J. Neurosci. 21:2001;5045-5053.
19. Arendt T., Holzer M., Gartner U. Neuronal expression of cyclin dependent kinase inhibitors of the INK4 family in Alzheimer's disease. J. Neural. Transm. 105(8/9):1998;949-960.
20. Lu K.P., Liou Y.C., Vincent I. Proline-directed phosphorylation and isomerization in mitotic regulation and Alzheimer's disease. BioEssays. 25:2003;174-181.
21. Nagy Z. Cell cycle regulatory failure in neurones: causes and consequences. Neurobiol. Aging. 21:2000;761-769.
22. Raina A.K., Pardo P., Rottkamp C.A., Zhu X., Pereira-Smith O.M., Smith M.A. Neurons in Alzheimer disease emerge from senescence. Mech. Ageing Dev. 123(1):2001;3-9.
23. Vincent I., Jicha G., Rosado M., Dickson D.W. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci. 17:1997;3588-3598.
24. Vincent I., Zheng J.H., Dickson D.W., Kress Y., Davies P. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol. Aging. 19:1998;287-296.
25. Goedert M., Spillantini M.G., Cairns N.J., Crowther R.A. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 8(1):1992;159-168.
26. Brion J.P., Anderton B.H., Authelet M., Dayanandan R., Leroy K., Lovestone S., Octave J.N., Pradier L., Touchet N., Tremp G. Neurofibrillary tangles and Tau phosphorylation. Biochem. Soc. Symp. 67:2001;81-88.
27. Delobel P., Flament S., Hamdane M., Delacourte A., Vilain J.P., Buée L. Modelling Alzheimer-specific abnormal Tau phosphorylation independently of GSK3β and pKA kinase activities. FEBS Lett. 516:2002;151-155.
28. Zheng-Fishhoffer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical- filament-like conformation. Eur. J. Biochem. 252:1998;542-552.
29. Buée-Scherrer V., Goedert M. Phosphorylation of microtubule-associated protein Tau by stress-activated protein kinases in intact cells. FEBS Lett. 515:2002;151-154.
30. Caillet-Boudin M.L., Delacourte A. Induction of a specific Tau Alzheimer epitope in SY-5Y neuroblastoma cells. NeuroReport. 8(1):1996;307-310.
31. Mailliot C., Bussière T., Hamdane M., Sergeant N., Caillet-Boudin M.L., Delacourte A., Buée L. Pathological Tau phenotypes: the weight of mutations, polymorphisms and differential neuronal vulnerabilities. Ann. NY Acad. Sci. 920:2000;107-114.
32. Vincent I., Rosado M., Davies P. Mitotic mechanisms in Alzheimer's disease. J. Cell Biol. 132:1996;413-425.
33. Jicha G.A., Lane E., Vincent I., Otvos L. Jr., Hoffmann R., Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J. Neurochem. 69:1997;2087-2095.
34. Lu P.J., Wulf G., Zhou X.Z., Davies P., Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated Tau protein. Nature. 399(6738):1999;784-788.
35. Husseman J.W., Nochlin D., Vincent I. Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol. Aging. 21:2000;815-828.
36. Delobel P., Flament S., Hamdane M., Mailliot C., Sambo A.-V., Begard S., Sergeant N., Delacourte A., Vilain J.P., Buée L. Abnormal Tau phosphorylation of the Alzheimer type also occurs during mitosis. J. Neurochem. 83:2002;412-420.
37. 1H NMR study on the binding of Pin1 WW domain with phosphothreonine peptides J. Biol. Chem. 276:2001;25150-25156.
38. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103:2002;26-35.
39. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402(6762):1999;615-622.
40. Bu B., Li J., Davies P., Vincent I. Deregulation of cdk5, hyperphosphorylation and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22:2002;6515-6525.
41. Iijima K., Ando K., Takeda S., Satoh Y., Seki T., Itohara S., Greengard P., Kirino Y., Nairn A.C., Suzuki T. Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J. Neurochem. 75:2000;1085-1091.
42. Tang D., Wang J. Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators. Prog. Cell Cycle Res. 2:1996;205-216.
43. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
44. Hamdane M, Sambo A-V, Delobel P, Bégard S, Violleau A, Delacourte A, Bertrand P, Benavides J, Buée L. Mitotic-like Tau phosphorylation by p25/Cdk5 kinase complex. J Biol Chem, submitted for publication.
45. Hamdane M., Smet C., Sambo A.-V., Leroy A., Wieruszeski J.M., Delobel P., Maurage C.A., Ghestem A., Wintjens R., Bégard S., Sergeant N., Delacourte A., Horvath D., Landrieu I., Lippens I., Buée L. Pin1, a therapeutic target in Alzheimer neurodegeneration. J. Mol. Neurosci. 19(3):2002;275-288.
46. Lu P.J., Zhou X.Z., Liou Y.C., Noel J.P., Lu K.P. Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function. J. Biol. Chem. 277:2002;2381-2384.
47. Holzer M., Gartner U., Stobe A., Hartig W., Gruschka H., Bruckner M.K., Arendt T. Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathol. 104:2002;471-481.
48. Ryo A., Nakamura M., Wulf G., Liou Y.C., Lu K.P. Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol. 3:2001;793-801.
49. Wulf G.M., Ryo A., Wulf G.G., Lee S.W., Niu T., Petkova V., Lu K.P. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:2001;3459-3472.
50. You H., Zheng H., Murray S.A., Yu Q., Uchida T., Fan D., Xiao Z.X. IGF-1 induces Pin1 expression in promoting cell cycle S-phase entry. J. Cell Biochem. 84:2002;211-216.
51. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
52. Ryo A., Liou Y.C., Lu K.P., Wulf G. Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer. J. Cell Sci. 116:2003;773-783.